Evidence map›Paper›PMID 33879893›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2020

[Semiquantitative parameters of

X H Liao, R F Wang, M Liu, X Q Chen, Y Xiong, L Nong, L Yin, B Y Zhang, Y J DU

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

X H LiaoDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
R F WangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
M LiuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
X Q ChenDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Y XiongDepartment of Pathology, Peking University First Hospital, Beijing 100034, China.
L NongDepartment of Pathology, Peking University First Hospital, Beijing 100034, China.
L YinDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
B Y ZhangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Y J DUDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Peking University · CNPeking University First Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the valuable predictors for evaluating progression-free survival (PFS) in patients with lung adenocarcinoma, we analyzed the potential roles of standardized uptake value (SUV)-derived parameters from

methodsData of 84 lung adenocarcinoma patients pre-treated, who underwent

resultsThe median follow-up period was 31 months (24 to 58 months). It was found that SUVmax (≥3.01), SUVmean (≥2.25), MTV (≥25.41 cm

conclusionHigh SUV-derived parameters (SUVmax, SUVmean, MTV and TLG) might provide prognostic value to some extent. Especially, TLG, and other clinical features [TNM stage, proGRP, TPA, ALP, and aPTTR] could be independently and significantly associated with PFS of lung adenocarcinoma patients. However,

Indexed as

Adenocarcinoma of LungLung NeoplasmsAnaplastic Lymphoma KinaseErbB ReceptorsFluorodeoxyglucose F18Genes, erbB-1HumansMutationPositron Emission Tomography Computed TomographyPrognosisRadiopharmaceuticalsRetrospective StudiesTumor BurdenAnaplastic Lymphoma KinaseErbB ReceptorsFluorodeoxyglucose F18RadiopharmaceuticalsAdenocarcinomaAnaplastic lymphoma kinaseEpidermal growth factor receptorLung neoplasmsPositron-emission tomography

Identifiers

PMID33879893
PMCPMC8072443
OpenAlexW3155850125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.